Guidant Receives Amended Offer from Boston Scientific; Guidant's Board to Evaluate Offer.INDIANAPOLIS -- Guidant Corporation (NYSE NYSE See: New York Stock Exchange :GDT GDT Global Descriptor Table GDT Geographic Data Technology Inc. GDT Gas Discharge Tube (energy, electrotechinical and electronics) GDT Getting Things Done GDT Geometric Dimensioning & Tolerancing GDT Ground Data Terminal ) acknowledges receipt today, January 12, 2006, of an amended offer from Boston Scientific The Boston Scientific Corporation (NYSE: BSX) (abbreviated BSC), is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, Corporation to acquire Guidant for $73 per Guidant share made up of a combination of half cash and half stock. The stock portion is subject to a collar. Guidant's recently amended merger agreement with Johnson & Johnson provides that each share of Guidant common stock would be exchanged for $37.25 in cash and .493 shares of Johnson & Johnson common stock. As of January 12, 2006, the Johnson & Johnson proposal was valued at $67.92 per Guidant share. Guidant's Board of Directors will evaluate all aspects of the offer from Boston Scientific, with the assistance of its investment bankers, JPMorgan Chase JPMorgan Chase (NYSE: JPM TYO: 8634 ) is one of the oldest financial services firms in the world. The company, headquartered in New York City, is one of the leaders in investment banking, financial services, asset and wealth management and private equity. With assets of $1. & Company and Morgan Stanley Guidant Corporation pioneers lifesaving technology, giving an opportunity for better life today to millions of cardiac and vascular patients worldwide. The company develops, manufactures and markets a broad array of products and services that enable less invasive care for some of life's most threatening medical conditions. For more information, visit www.guidant.com. Guidant Corporation and Johnson & Johnson have filed with the Securities and Exchange Commission (SEC) a definitive proxy statement/prospectus and other documents regarding the proposed merger between Guidant and Johnson & Johnson. Investors are urged to read the definitive proxy statement/prospectus and any other relevant documents filed with the SEC because they contain important information. The proxy statement/prospectus and other documents filed by Johnson & Johnson and Guidant with the SEC are available free of charge at the SEC's website, www.sec.gov, or by directing a request to Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933, Attention: Investor Relations Investor relations The process by which the corporation communicates with its investors. ; or by directing a request to Guidant Corporation, 111 Monument Circle, #2900, Indianapolis, IN 46204-5129, Attention: Investor Relations. Guidant Corporation, its directors, and certain of its executive officers may be considered participants in the solicitation of proxies in connection with the proposed transactions. Information about the directors and executive officers of Guidant and their ownership of Guidant stock is set forth in Guidant's most recent filing on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. . Investors may obtain additional information regarding the interests of such participants by reading the definitive proxy statement/prospectus. |
|
||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion